Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hilleman Laboratories Pvt. Ltd.

https://www.hillemanlabs.org/

Latest From Hilleman Laboratories Pvt. Ltd.

Global R&D Heads Talk Superbugs, PROTACs And More

A panel of R&D experts from Merck’s EMD Serono, Boehringer Ingelheim, Takeda and Hilleman Labs discuss technologies like PROTACs and multi-specific antibodies, a superbug that could cause more damage than COVID-19 and the need for harmonized regulation that recognizes risk is essential to discovery

Research & Development Innovation

Is India’s Budget Bad News For COVID-19 Boosters, New Vaccines?

India’s 2022-23 budget cuts the outlay for COVID-19 vaccines to a seventh the previous amount. Is that worrying or does it leave the door open for private sales of vaccines? With over 75% of the country's adult population now fully vaccinated, what does it mean for booster shots and yet to be approved SARS-CoV-2 vaccines?

India Coronavirus COVID-19

Pediatric COVID-19 Vaccine Face-Off Looms As Bharat Biotech Heads For Approval

While Bharat Biotech is close to an accelerated approval of Covaxin in two to 18-year-olds, Zydus Cadila is yet to roll out its COVID-19 vaccine in India. As they head to a face-off in pediatric vaccines, the former faces manufacturing constraints and the latter hesitance over a first of its kind DNA vaccine. Experts speak to Scrip on which one stands a better chance of winning.

Coronavirus COVID-19 Vaccines

Ex-Hilleman CEO On COVID-19 Vaccine Heterologous Boosting, Endemic Disease

As more countries adopt heterologous boosting of COVID-19 vaccines in a bid to improve supplies and/or immunity while reducing side effects, vaccines expert and ex-Hilleman CEO Davinder Gill talks to Scrip in an audio interview on the challenges of the strategy and of the disease becoming endemic.

Coronavirus COVID-19 Vaccines
See All

Company Information

  • Industry
  • Academic and Research Institutions
UsernamePublicRestriction

Register